WASHINGTON, DC – House Energy and Commerce Committee leaders are concerned with a Department of Justice filing suggesting the Federal Communications Commission (FCC) should limit participation in spectrum auctions authorized by the Middle Class Tax Relief and Job Creation Act.
WASHINGTON, DC – The House Energy and Commerce Committee today announced its schedule for the week of April 22, 2013. Beginning on Wednesday, the Oversight and Investigations Subcommittee continues its rigorous oversight of Obamacare with an examination of the health care law’s implementation. On Thursday, the Health Subcommittee will review a discussion draft of “track and trace” legislation to secure pharmaceuticals while the Communications and Technology Subcommittee will examine the Universal Service Fund’s Lifeline program.
“This bill would defund an Obamacare political slush fund controlled by HHS Secretary Kathleen Sebelius and instead use the money to give the sickest Americans health insurance. ATR is supportive of this legislation… H.R.
WASHINGTON, DC – The Commerce, Manufacturing, and Trade Subcommittee, chaired by Rep. Lee Terry (R-NE), today held a hearing to examine the Global Investment in American Jobs Act of 2013. Chairman Terry put forward this draft legislation to help increase foreign direct investment in the United States and spur job creation.
Committee Continues Bipartisan Review of Renewable Fuel Standard with Examination of Agricultural ImpactsApril 18, 2013 | Press Release
WASHINGTON, DC – The House Energy and Commerce Committee is continuing its bipartisan review of the Renewable Fuel Standard (RFS), releasing today the second in a series of white papers examining a number of issues emerging with the current system. Energy and Commerce Committee Chairman Fred Upton (R-MI) and Ranking Member Henry A.
WASHINGTON, DC – Energy and Commerce Committee Chairman Fred Upton (R-MI) and U.S. Senator Tom Coburn, M.D. (R-OK), Ranking Member on the Homeland Security and Governmental Affairs Committee, issued the following statement regarding the Food and Drug Administration’s ruling to not approve opioid drug applications reliant upon previous approvals which did not require abuse-deterrent properties: